Form 4: Avidity Director Sells Shares, Options in Novartis Merger

Avidity Biosciences Director Carsten Boess disposed of common stock and stock options on February 27, 2026, as part of the previously announced merger with Novartis AG.

Summary

• Director Carsten Boess of Avidity Biosciences, Inc. (RNAM) disposed of all his beneficial ownership in the company.
• The transactions occurred on February 27, 2026, pursuant to an Agreement and Plan of Merger dated October 25, 2025.
• Novartis AG, through its indirect wholly owned subsidiary Ajax Acquisition Sub, Inc., is acquiring Avidity Biosciences.
• Boess disposed of 6,692 shares of common stock, inclusive of shares issuable upon settlement of previously reported restricted stock units.
• He also disposed of multiple tranches of stock options totaling 103,381 shares.
• Stock options were exchanged for a cash payment equal to the merger consideration of $72.00 per share minus the respective exercise price.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development for Avidity Biosciences shareholders and option holders, as it confirms the execution of a merger at a significant premium, providing a clear and favorable exit.

Positives

• The merger consideration of $72.00 per share provides a clear exit value for shareholders and option holders.
• The transaction indicates the successful completion or near completion of the merger with Novartis AG.
• Option holders received cash for the in-the-money value of their options, indicating a positive outcome for those equity incentives.

Negatives

• The disposition of all shares and options by a director suggests the company will cease to exist as an independent publicly traded entity, removing investment opportunities in Avidity Biosciences.

Future Outlook

The filing indicates the impending or completed acquisition of Avidity Biosciences by Novartis AG, suggesting Avidity will no longer operate as an independent public entity.

Industry Context

StockSavvy.ai notes that this Form 4 filing confirms the progression of the acquisition of Avidity Biosciences by Novartis AG, a common trend in the biotechnology and pharmaceutical sectors where larger companies acquire innovative smaller firms to bolster their pipelines and market share. This particular merger highlights the strategic value placed on Avidity's assets by a major pharmaceutical player like Novartis.

Comparison to Industry Standards

• The merger consideration of $72.00 per share for Avidity Biosciences represents a significant premium over its pre-merger trading price (implied by the option exercise prices ranging from $8.82 to $39.96).
• This valuation is consistent with recent acquisitions in the biotech sector, such as Pfizer's acquisition of Seagen for $43 billion ($229 per share) or Merck's acquisition of Prometheus Biosciences for $10.8 billion ($200 per share), where innovative drug platforms command substantial premiums.
• The cash payment for in-the-money options is a standard practice in such M&A transactions, ensuring equity incentive holders are compensated for their vested interests.

Management Changes

Stakeholder Impact

• Shareholders: Received or will receive $72.00 per share in cash, representing a positive return.
• Employees (with options): Received cash for their in-the-money options, providing a financial benefit.
• Company (Avidity): Will be integrated into Novartis AG, losing its independent corporate identity.

Next Steps

• Completion of the merger with Novartis AG.
• Avidity Biosciences ceasing to be an independent publicly traded company.

Key Dates

Keywords

Avidity Biosciences, RNAM, Novartis AG, Merger, Acquisition, Form 4, Insider Trading, Stock Options, Common Stock, Biotechnology, Pharmaceuticals